Yatindra Joshi, Ph.D., MBA
Yatindra M. Joshi, Ph.D., founder of YMJ Consultants LLC. He is also the Chairman of the Board of Neoprol Ltd and is a member of the Board of Tapemark, Cutis Pharmaceuticals, Virtus Pharmaceuticals, and InvaGen Pharmaceuticals. He is a seasoned executive with 31 years of pharmaceutical R&D experience and a unique combination of strong business and technical skills. He has had a successful track record of developing branded and generic products with varying complexity and variety of dosage forms from the laboratory to commercialization. He has demonstrated leadership, interpersonal, communication, and management skills, vision and drive to achieve organizational excellence, ability to recruit and retain talent, and skill set and personality to create and maintain a high-performance organization. He has authored 29 publications and has 19 patents. He received his BS and MS degrees in Chemistry from Delhi University, Delhi, India, Ph.D. in Chemistry from Dalhousie University, Halifax, NS, Canada, and MBA from the Wharton School of Business, University of Pennsylvania.
Lawrence Bell, JD, MBA
Larry is a Partner and Co-head of the firm’s corporate practice group at Golenbock, Eiseman, Assor, Bell and Peskoe LLP. His practice focuses on the representation of private equity funds and strategic investors in international and domestic mergers, acquisitions, public and private capital raising transactions, including private equity, venture capital and public offerings, equity and investment grade and high yield debt financings, companies engaged in technology transfer and licensing, private and public emerging growth companies, venture capital funds, and participants in leveraged buyouts, venture capital and “growth equity” financings, spin-outs, complex financing transactions, and trustees and classes of note holders in connection with debt restructurings. He works with companies and funds and other investors in the fields of new media, technology (including companies engaged in the development of proprietary software, systems, information technology, medical devices and bio-pharmaceuticals), health and nutrition products, specialty chemicals, minerals, power generation equipment and other manufacturing, financial services, investment management, communications, technology-related services and consumer products.
David Fink, MBA
David has had distinguished career in the pharma industry. He led the US HIV and Westwood Squibb businesses at BMS and the ID, Dermatology and CNS businesses at Schering and several specialty pharma companies as GM, Commercial Lead and/or Corporate Officer. He also commercially developed and launched over 20 products across numerous therapeutic areas, and built seven commercial organizations and led numerous BD acquisitions, licensing and strategic alliances.
Carl E. Mangum, CPA
Carl has over 45 years of diversified business, consulting, tax and public accounting experience gaining extensive knowledge and experience in high technology and other businesses, including the telecommunications, computer hardware, intellectual property, software, managed services, e-commerce and medical related sectors. He has assisted numerous technology companies in both the formative stages and the fully developed stages of their business. He has extensive experience in venture capital and other financings, Initial Public Offerings (“IPO’s”), and acquisition and merger transactions.